Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhenkun Ma

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Journal of Medicinal Chemistry|May 2, 2017
7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral LeishmaniasisAndrew M Thompson, Patrick D O'Connor, Andrew J Marshall, et al.
The Lancet. Infectious Diseases|September 13, 2025
Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trialZhiqiang Song, Liya Zhou, Weihong Wang, et al.
Journal of Medicinal Chemistry|August 31, 2012
Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosisDongfeng Zhang, Yu Lu, Kai Liu, et al.
Journal of Medicinal Chemistry|February 17, 2022
Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial PathogensZhenkun Ma, Shijie He, Ying Yuan, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2004
Novel inhibitors of bacterial protein synthesis: structure-activity relationships for 1,8-naphthyridine derivatives incorporating position 3 and 4 variantsRichard F Clark, Sanyi Wang, Zhenkun Ma, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 19, 2013
Identification of a small molecule with activity against drug-resistant and persistent tuberculosisFeng Wang, Dhinakaran Sambandan, Rajkumar Halder, et al.
Antimicrobial Agents and Chemotherapy|August 10, 2016
Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA SynthetaseAndrés Palencia, Xianfeng Li, Wei Bu, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Journal of Medicinal Chemistry|May 2, 2017
7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral LeishmaniasisAndrew M Thompson, Patrick D O'Connor, Andrew J Marshall, et al.
The Lancet. Infectious Diseases|September 13, 2025
Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trialZhiqiang Song, Liya Zhou, Weihong Wang, et al.
Journal of Medicinal Chemistry|August 31, 2012
Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosisDongfeng Zhang, Yu Lu, Kai Liu, et al.
Journal of Medicinal Chemistry|February 17, 2022
Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial PathogensZhenkun Ma, Shijie He, Ying Yuan, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2004
Novel inhibitors of bacterial protein synthesis: structure-activity relationships for 1,8-naphthyridine derivatives incorporating position 3 and 4 variantsRichard F Clark, Sanyi Wang, Zhenkun Ma, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 19, 2013
Identification of a small molecule with activity against drug-resistant and persistent tuberculosisFeng Wang, Dhinakaran Sambandan, Rajkumar Halder, et al.
Antimicrobial Agents and Chemotherapy|August 10, 2016
Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA SynthetaseAndrés Palencia, Xianfeng Li, Wei Bu, et al.
Pageof 7